AI Article Synopsis
- HIV2 is prevalent in West Africa, with a 2% estimated prevalence in Burkina Faso; the study aimed to assess patient follow-up and data availability.
- A cross-sectional study from June to December 2017 involved patients 18 years and older, collecting various data to analyze HIV2 infection rates and treatment efficacy.
- The study found a 4.3% infection rate, a high retention rate in care (70%), and significant immunological improvement, with most patients staying in treatment after five years.
Article Abstract
HIV2 is endemic in West Africa. In Burkina Faso, its prevalence was estimated at 2%. The aim of this work was to evaluate the follow-up of patients and also to contribute to the availability of data. We involved 18 years or older. Infection was screened according to the national algorithm. A cross- sectional study from first June 2017 to 31 December 2017 was performed. For each patient, sociodemographic, clinical, biological, therapeutic and evolution data were collected and analyzed. The proportion of patients infected with HIV2 (n = 48; 1.7%) and HIV2 + 1 (n = 67; 2.4%) was 4.3%. The sex rat mean age was 50.3 ± 8.5 years. The combination of 2INTI + LPV/r was the most prescribed (n = 73; 63.5%). The average gain of LTCD4 has evolved from + 236 cells/mm in 2011 to + 364 cells/mm in 2015. The retention rate at grade 5 was about 70%. The immunological and clinic response of the patients was satisfactory. More than half of the patients remained in the continuum of care after five years of follow-up.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732798 | PMC |
| http://dx.doi.org/10.1177/23259582221143675 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!